Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 3, 2025
Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
GlobeNewswire
·
April 3, 2025
NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced data from a poster presentation …
Breaking News: Early Clinical Trial on Plant-Based Finasteride Alternative Shows Exciting Results Amid Growing Concerns Over Drug Side Effects
GlobeNewswire
·
April 3, 2025
CLEVELAND, April 03, 2025 (GLOBE NEWSWIRE) -- The hair loss industry is at a tipping point. A recent Wall Street Journal exposé has reignited concerns about the severe and long-term side effects of finasteride, the FDA-approved drug for male pattern …
Ligandrol (LGD-4033) SARMs: Ligandrol Benefits, Ligandrol Results & Buy Ligandrol Pills Alternatives Ligan 4033 By CrazyBulk
GlobeNewswire
·
April 3, 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to know you in our free private CrazyBulk community. And you’ll receive an invite to it the minute you purchase any CrazyBulk product. These …
Sai Life Sciences sets up Peptide Research Center in India
GlobeNewswire
·
April 3, 2025
HYDERABAD, India, April 03, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at …
Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”
GlobeNewswire
·
April 3, 2025
AURORA, Colo., April 03, 2025 (GLOBE NEWSWIRE) -- Arialief caught my attention from the very first day I heard about it. It’s not every day I commit to testing a new supplement for over three months and then share my personal journey. As someone who has …
Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
GlobeNewswire
·
April 3, 2025
ST. PETERSBURG, Fla., April 03, 2025 (GLOBE NEWSWIRE) -- Prime Biome caught my attention the very first day I heard about it. It’s not every day that I commit to a new supplement for nearly four months and then share my entire journey. But after …
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
GlobeNewswire
·
April 3, 2025
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer. Basel, Switzerland, Thursday, 03.04.2025 – Today NBE …
Vítej, budoucnosti. Endoskopický systém ELUXEO® 8000
GlobeNewswire
·
April 3, 2025
RATINGEN, Německo, April 03, 2025 (GLOBE NEWSWIRE) -- Tým FUJIFILM Healthcare Europe s potěšením oznamuje evropské uvedení svého pokročilého endoskopického systému ELUXEO® 8000* s novými terapeutickými možnostmi, řízením pracovních postupů a lepší kvalitou …
Welcome, Future. ELUXEO® 8000-Endoskopiesystem
GlobeNewswire
·
April 3, 2025
RATINGEN, Deutschland, April 03, 2025 (GLOBE NEWSWIRE) -- Das Team von FUJIFILM Healthcare Europe freut sich, die Markteinführung von ELUXEO® 8000* in Europa bekannt zu geben, unserem neuen fortschrittlichen Endoskopiesystem mit neuen therapeutischen …
Welcome, Future. Sistema endoscopico ELUXEO® 8000
GlobeNewswire
·
April 3, 2025
RATINGEN, Germania, April 03, 2025 (GLOBE NEWSWIRE) -- Il team FUJIFILM Healthcare Europe è entusiasta di annunciare l’uscita in Europa di ELUXEO® 8000*, il nostro nuovo sistema endoscopico avanzato che include nuove capacità terapeutiche, gestione del …
Welcome, Future (Bem-vindo, futuro). Sistema de endoscopia ELUXEO® 8000
GlobeNewswire
·
April 3, 2025
RATINGEN, Alemanha, April 03, 2025 (GLOBE NEWSWIRE) -- A equipa da FUJIFILM Healthcare Europe tem o prazer de anunciar o lançamento na Europa do ELUXEO® 8000*, o novo sistema de endoscopia avançada com novas capacidades terapêuticas, gestão do fluxo de …
Welcome, Future (Bienvenido, futuro). Sistema de endoscopia ELUXEO® 8000
GlobeNewswire
·
April 3, 2025
RATINGEN, Alemania, April 03, 2025 (GLOBE NEWSWIRE) -- Al equipo de FUJIFILM Healthcare Europe nos complace anunciar el lanzamiento de ELUXEO 8000, nuestro nuevo sistema de endoscopia avanzado con nuevas capacidades terapéuticas, gestión del flujo de …
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
GlobeNewswire
·
April 3, 2025
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the …
Welcome, Future. ELUXEO® 8000 Endoscopy System
GlobeNewswire
·
April 3, 2025
RATINGEN, Germany, April 03, 2025 (GLOBE NEWSWIRE) -- The FUJIFILM Healthcare Europe Team are excited to announce the European launch of ELUXEO® 8000*, our new advanced endoscopy system with new therapeutic capabilities, workflow management and improved …
Welcome, Future (Welkom, toekomst). ELUXEO® 8000 Endoscopy-systeem
GlobeNewswire
·
April 3, 2025
RATINGEN, Duitsland, April 03, 2025 (GLOBE NEWSWIRE) -- Het FUJIFILM Healthcare Europe-team kondigt met trots de Europese lancering aan van ELUXEO® 8000*, ons nieuwe geavanceerde endoscopiesysteem met nieuwe therapeutische mogelijkheden, workflowmanagement …
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
GlobeNewswire
·
April 3, 2025
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and …
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé
GlobeNewswire
·
April 3, 2025
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé Désignation accordée pour l’anémie hémolytique à anticorps chauds et la maladie …
Veteran Banker Joins Avextra’s Supervisory Board
GlobeNewswire
·
April 3, 2025
News Release Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board, bringing decades of experience in corporate finance, M…
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt
GlobeNewswire
·
April 3, 2025
HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (im Folgenden kurz „FibroBiologics“), ein im klinischen Stadium tätiges Biotechnologieunternehmen mit über 240 erteilten und angemeldeten Patenten für die Entwicklung von …
FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
GlobeNewswire
·
April 3, 2025
HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique détenant plus de 240 brevets délivrés et en instance portant sur le développement de thérapies et de …